RecruitingPhase 4ACTRN12605000246684

Safety of Tramadol in Breastfeeding

Safety of Tramadol in Breastfeeding - A Study of the Postoperative Use of Tramadol following Caesarian Section


Sponsor

Professor Michael Paech

Enrollment

75 participants

Start Date

Apr 3, 2004

Study Type

Interventional

Conditions

Summary

In this study we wish to find out how much of the pain relieving drug tramadol, given to women after caesarean section, passes into breast milk. The information will be used to inform lactating women about the risk versus benefit of taking tramadol during early breast feeding. Tramadol has been used overseas for many years but only became available in Australia in 1998. It is now widely used in the treatment of many types of pain and is particularly useful after surgery. There is very little information about the transfer of tramadol and its break-down products into breast milk. One study looking at a single dose of tramadol suggests single doses are unlikely to be a problem, but there is not enough information to be certain about the safety of tramadol for new-born babies when mothers who are breast feeding are taking repeated doses. If the infant was affected in any way this would probabvly be seen as sleepiness, floppiness and poor feeding. We aim to obtain iformation about how much tramadol passes to the breast feeding infant and be able to advise about the likelihood of significant adverse effects. 75 women taking oral tramadol regularly (100 mg every 6 hours)for postoperative pain control will be recruited after removal of their patient controlled epidural analgesia device, usually on day 3 post caesarean section. Breast milk samples will be taken just before the fourth dose and in between the 4th and 5th doses along with a single blood sample. The milk and blood sample will be sent to the laboratory to measure the amount of tramadol and its break-down product. The baby will also be assessed afte the 4th dose for tone and alertness.


Eligibility

Sex: Females

Plain Language Summary

Simplified for easier understanding

This study is looking at how much of a pain relief drug called tramadol passes into breast milk after women take it following a caesarean section (C-section). Tramadol is commonly used after surgery to manage pain, but there is not much information about whether it is safe for babies who are being breastfed. Researchers want to measure how much of the drug reaches breast milk so they can advise new mothers about the risks and benefits. You may be eligible if: - You are a woman who has had a caesarean section and is now on day 3 after the operation - You are breastfeeding - You are willing to take tramadol as part of your pain relief - Your epidural catheter has been removed - You are in generally good health (ASA class 1 or 2) You may NOT be eligible if: - You have a known sensitivity or allergy to tramadol - You have significant kidney problems - You have decided not to breastfeed Talk to your doctor about whether this trial might be right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Tramadol is widely used in breastfeeding but it is unclear exactly how much is transferred into breast milk. This study will look at levels of tramadol and its metabolite (M1) in breast milk and blood

Tramadol is widely used in breastfeeding but it is unclear exactly how much is transferred into breast milk. This study will look at levels of tramadol and its metabolite (M1) in breast milk and blood after regular administration (100 mg 6 hourly). Milk samples will be taken immediately prior to 4th dose, and 2 more samples plus one blood sample taken in dosing interval between 4th and 5th doses. Baby also assessed for tone and alertness after 4th dose.


Locations(1)

Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12605000246684